Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $185.00.

Truist analyst David MacDonald raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $182 and keeps a Hold rating on the ...

This was the stock's fourth consecutive day of losses.

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to ...

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity ...

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine ...

This was the stock's second consecutive day of losses.

QUEST DIAGNOSTICS ($DGX) is expected to release its quarterly earnings data on Tuesday, April 22nd before market open, per Finnhub. Analysts are expecting revenue of ...